Saturday, May 18, 2013 Last update: 9:34 AM
Company Tech News as it Breaks
Trade Events
Medgenics, Inc.
News articles for Medgenics, Inc.:
Wednesday, May 1, 2013
- Medgenics Announces Results of 2013 Annual Meeting of StockholdersMedgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”),, the developer of a novel technology for the sustained production and delivery of therapeutic proteins ... read more
Thursday, April 25, 2013
- Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis PatientsMedgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in ... read more
Monday, April 22, 2013
- Medgenics Receives Notice of Allowance from the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic ProteinsMedgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in ... read more
Thursday, April 18, 2013
- Medgenics to Present at the 12th Annual Needham Healthcare ConferenceMedgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic ... read more
Tuesday, March 26, 2013
- Medgenics Announces Exercise by Underwriters of Over-Allotment OptionMedgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic ... read more
Friday, March 15, 2013
- Medgenics to Present at the 25th Annual Roth ConferenceMedgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic ... read more
Thursday, December 6, 2012
- Medgenics Key Patent Claims Allowed in Japan Protecting Core Technology to be Used in Hepatitis TreatmentMedgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients ... read more
Wednesday, November 28, 2012
- Renowned Experts Affirm Potential of Medgenics’ INFRADURE Technology for the Treatment of Hepatitis B and DMedgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients ... read more
Wednesday, November 21, 2012
- Medgenics Granted U.S. Patent for Core Technology Used in Sustained Delivery of Erythropoietin, Aimed at Multi-Billion Dollar Anemia MarketMedgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in ... read more